|
注册号: Registration number: |
ChiCTR2300074922 |
|
最近更新日期: Date of Last Refreshed on: |
2024-01-15 21:46:39 |
|
注册时间: Date of Registration: |
2023-08-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
比较宫腔镜下子宫憩室整复术与期待治疗子宫小憩室伴继发不孕患者的妊娠结局的研究:一项随机平行对照试验 |
|
Public title: |
Effectiveness of hysteroscopic niche resection versus expectant management in patients with secondary infertility and a small uterine caesarean scar defect on reproductive outcomes: a randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
比较宫腔镜下子宫憩室整复术与期待治疗子宫小憩室伴继发不孕患者的妊娠结局的研究:一项随机平行对照试验 |
|
Scientific title: |
Effectiveness of hysteroscopic niche resection versus expectant management in patients with secondary infertility and a small uterine caesarean scar defect on reproductive outcomes: a randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘璟蓝 |
研究负责人: |
刘璟蓝 |
|
Applicant: |
Jinglan Liu |
Study leader: |
Jinglan Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 180 1731 0157 |
研究负责人电话:
Study leader's |
+86 180 1731 0157 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jinglan.liu@163.com |
研究负责人电子邮件: Study leader's E-mail: |
jinglan.liu@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区衡山路910号 |
研究负责人通讯地址: |
上海市徐汇区衡山路910号 |
|
Applicant address: |
910 Hengshan Road, Xuhui District, Shanghai |
Study leader's address: |
910 Hengshan Road, Xuhui District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
200030 |
研究负责人邮政编码: Study leader's postcode: |
200030 |
|
申请人所在单位: |
国际和平妇幼保健院 |
||
|
Applicant's institution: |
The International Peace Maternity and Child Health Hospital |
||
|
研究负责人所在单位: |
国际和平妇幼保健院 |
||
|
Affiliation of the Leader: |
The International Peace Maternity and Child Health Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
GKLW-A-2023-026-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属国际和平妇幼保健院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-03 00:00:00 | ||
|
伦理委员会联系人: |
张延菲 |
||
|
Contact Name of the ethic committee: |
Yanfei Zhang |
||
|
伦理委员会联系地址: |
上海市徐汇区衡山路910号 |
||
|
Contact Address of the ethic committee: |
910 Hengshan Road, Xuhui District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 64070434 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
国际和平妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区衡山路910号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
910 Hengshan Road, Xuhui District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
院内 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hospital-raised |
||||||||||||||||||||||
|
研究疾病: |
子宫憩室 |
||||||||||||||||||||||
|
Target disease: |
Cesarean scar defect |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较宫腔镜下子宫憩室整复术与期待治疗后子宫憩室合并不孕患者的妊娠结果。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare the pregnancy outcomes in women with uterus cesarean scar defect after hysteroscopic niche resection versus expectant management. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.有明确的手术或麻醉(全麻或局麻)禁忌证; 2.已确定的妊娠; 3.3个月内接受过相关影响观察指标的治疗措施; 4.合并宫颈上皮内病变、盆腔急性感染或慢性感染急性发作、可疑或确定的恶性肿瘤或合并需要切除的病变(子宫内膜非典型细胞)、凝血功能异常、与宫腔交通的输卵管积水; 5.排卵障碍、输卵管性不孕、子宫内膜异位症、子宫粘膜下肌瘤引起的不孕; 6.合并有手术指征的子宫肌瘤、卵巢肿瘤; 7.存在妊娠禁忌证。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Contraindication to surgery or anaesthesia (general or local); 2. Established pregnancy; 3. Relevant treatment affecting the observed indicators within 3 months; 4. Combined cervical dysplasia, acute infection of the pelvis or acute attack of chronic infection, suspected or known malignancy or combined benign lesions requiring hysterectomy ( atypical endometrial cells), dysfunction of coagulation,hydrosalpinx communicating with the uterus; 5. Infertility caused by ovulatory dysfunction, tubal disorders, endometriosis and submucosal fibroids; 6. With myomas and oophoritic cyst that should be treated by operation; 7. Contraindication to pregnancy. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-09-01 00:00:00至 To 2026-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-09-01 00:00:00 至 To 2024-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
当临床评估并符合随机化条件时,研究员临床资料录入互联网数据库,基于互联网中央随机系统确定随机号,患者将严格地按随机号进行随机分配。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
When clinically evaluated and eligible for randomization, the investigator will enter the clinical information into the Internet database, determine the randomization number based on a centralized Internet randomization system, and patients will be randomly assigned strictly by randomization number. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
根据研究设计及内容制定CRF,通过CRF进行数据采集及管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Develop CRF according to the study design and content, data collection and management through CRF. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |